Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710067 · ClinicalTrials.gov registry record
Urine Metabolites in the Diagnosis of Disease
A clinical trial of Colorectal Cancer and Crohn Disease, sponsored by Luventix.
- Recruiting
- Registry status
- 1,250
- Enrollment target
- 4
- Study locations
NCT06710067: Recruiting study of Colorectal Cancer and Crohn Disease, sponsored by Luventix.
NCT06710067 is a study of Colorectal Cancer and Crohn Disease that is actively recruiting participants, run by Luventix. The registered enrollment target is 1,250 participants, below the 1,541-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (19% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06710067, a study of Colorectal Cancer and Crohn Disease, is actively recruiting participants, sponsored by Luventix.
- RECRUITING
- Registry status
- 1,250 participants
- Enrollment target
- 4
- Study locations
Study Summary
The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including colorectal cancer, small intestinal bacterial overgrowth (SIBO), Crohn\'s disease, and Celiac disease, collect urine samples and clinical data, and use artificial intelligence and machine learning to build disease-specific models which can identify and differentiate a participants' specific GI disease. The main questions it aims to answer are: 1. Does the platform identify a disease signal within each disease cohort, compared to normal controls? 2. How well does the test perform (e.g. sensitivity and specificity/false-positive rate)?
Primary Outcome
Disease signal detection quantification within each disease cohort, compared to normal controls.
Conditions Studied
Study Locations (4)
California
- Unio Health Partners (Gastroenterology) - Encinitas
- Digestive Health Associates - Santa Monica
- Westside Gastro Care - Santa Monica
- Bass Medical Group (Gastroenterology) - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2026-09 |
What NCT06710067 shows while recruiting
NCT06710067 is an observational study that tracks outcomes without assigning an intervention. Its 1,250 participants enrollment target places it among the larger protocols in the corpus, below the 1,541-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (19% lower).
The record links to 4 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06710067 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06710067 about?
NCT06710067 is a clinical study titled "Urine Metabolites in the Diagnosis of Disease". The goal of this observational study is to validate a non-invasive, urine-based diagnostic technology for the detection and differentiation of various gastrointestinal (GI) diseases. This research study intends to enroll participants across a range of demographics and GI disease states including co...
What is the current status of trial NCT06710067?
This trial is currently recruiting. The enrollment target is 1,250 participants. The study started on 2024-10-01. Estimated completion is 2026-09.
What conditions does trial NCT06710067 study?
This clinical trial studies the following conditions: Colorectal Cancer, Crohn Disease, Celiac Disease, Small Intestinal Bacterial Overgrowth Syndrome (SIBO).
Who is sponsoring clinical trial NCT06710067?
This trial is sponsored by Luventix, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06710067 being conducted?
This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06710067's enrollment target sits among peer trials
1,250 39th of 381 higher than 343 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI